- Home
- SRTS vs BYSI Comparison
SRTS vs BYSI Comparison
Compare SRTS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- BYSI
- Stock Information
- Founded
- SRTS 2010
- BYSI 2010
- Country
- SRTS United States
- BYSI United States
- Employees
- SRTS N/A
- BYSI N/A
- Industry
- SRTS Medical/Dental Instruments
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- BYSI Health Care
- Exchange
- SRTS Nasdaq
- BYSI Nasdaq
- Market Cap
- SRTS 75.5M
- BYSI 80.6M
- IPO Year
- SRTS 2016
- BYSI 2017
- Fundamental
- Price
- SRTS $3.39
- BYSI $1.72
- Analyst Decision
- SRTS Strong Buy
- BYSI
- Analyst Count
- SRTS 3
- BYSI 0
- Target Price
- SRTS $8.00
- BYSI N/A
- AVG Volume (30 Days)
- SRTS 211.1K
- BYSI 26.7K
- Earning Date
- SRTS 08-07-2025
- BYSI 08-13-2025
- Dividend Yield
- SRTS N/A
- BYSI N/A
- EPS Growth
- SRTS N/A
- BYSI N/A
- EPS
- SRTS N/A
- BYSI N/A
- Revenue
- SRTS $37,564,000.00
- BYSI N/A
- Revenue This Year
- SRTS N/A
- BYSI N/A
- Revenue Next Year
- SRTS $33.38
- BYSI N/A
- P/E Ratio
- SRTS N/A
- BYSI N/A
- Revenue Growth
- SRTS 3.29
- BYSI N/A
- 52 Week Low
- SRTS $3.03
- BYSI $0.98
- 52 Week High
- SRTS $9.33
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- SRTS 39.05
- BYSI 35.50
- Support Level
- SRTS $3.08
- BYSI $1.96
- Resistance Level
- SRTS $3.45
- BYSI $1.84
- Average True Range (ATR)
- SRTS 0.20
- BYSI 0.12
- MACD
- SRTS 0.01
- BYSI -0.01
- Stochastic Oscillator
- SRTS 82.00
- BYSI 0.00
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.